Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL

The high complete remission rate with first-line combined fludarabine, cyclophosphamide, and rituximab (FCR) begs the question of the value of minimal residual disease (MRD)–negative status as a treatment end point. We report on 237 patients with chronic lymphocytic leukemia who received first-line...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Strati, Paolo, Keating, Michael J., O'Brien, Susan M., Burger, Jan, Ferrajoli, Alessandra, Jain, Nitin, Tambaro, Francesco Paolo, Estrov, Zeev, Jorgensen, Jeffrey, Challagundla, Pramoda, Faderl, Stefan H., Wierda, William G.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Hematology 2014
Ämnen:
Clinical Trials and Observations
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4067501/
https://ncbi.nlm.nih.gov/pubmed/24705492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-11-538116
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk